公开(公告)号：US11965020B2

公开(公告)日：2024-04-23

申请号：US18318871

申请日：2023-05-17

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Tong Zhang ,  Erica Pyles ,  Michael Rosconi ,  Nina Liu ,  Supriya Patel ,  Eric Smith ,  Andrew Murphy ,  Chia-Yang Lin ,  Samuel Davis

IPC分类号： C07K16/24 ,  A61K39/395 ,  A61K47/68 ,  C07K16/28 ,  C07K16/30

CPC分类号： C07K16/244 ,  A61K39/395 ,  A61K47/6845 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

公开(公告)号：US11937587B2

公开(公告)日：2024-03-26

申请号：US17118241

申请日：2020-12-10

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Kara L. Olson ,  Eric Smith ,  Ka-Man Venus Lai ,  Andrew J. Murphy ,  Gavin Thurston ,  Dayong Guo

IPC分类号： A01K67/027 ,  C07K14/725 ,  C12N5/071 ,  C12N15/85 ,  G01N33/50

CPC分类号： A01K67/0278 ,  A01K67/0276 ,  C07K14/7051 ,  C12N5/0602 ,  C12N15/8509 ,  G01N33/5088 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/03 ,  A01K2267/0337 ,  Y02A50/30

摘要： Non-human animals, expressing humanized CD3 proteins are provided. Non-human animals, e.g., rodents, genetically modified to comprise in their genome humanized CD3 proteins are also provided. Additionally, provided are methods and compositions of making such non-human animals, as well as methods of using said non-human animals.

公开(公告)号：US20240067691A1

公开(公告)日：2024-02-29

申请号：US18451797

申请日：2023-08-17

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Eva-Maria WEICK ,  Nicolin BLOCH ,  Vidur GARG ,  Erica ULLMAN ,  Tong ZHANG ,  Chia-Yang LIN ,  Jiaxi WU ,  Eric Smith

IPC分类号： C07K14/56 ,  C07K14/715

CPC分类号： C07K14/56 ,  C07K14/7156 ,  A61K38/00 ,  C07K2319/30

摘要： The present disclosure provides interferon receptor agonists with improved safety profiles and therapeutic indices. The interferon receptor agonists are attenuated through masking and/or reduced receptor binding as compared to a wild-type interferon. IFN receptor agonists optionally further comprise a targeting moiety, e.g., a targeting moiety that recognizes a tumor- or immune cell-associated antigen and directs the interferon receptor agonist to a tumor site and/or tumor-reactive immune cells. The disclosure further provides pharmaceutical compositions comprising the interferon receptor agonists, and methods of use of the interferon receptor agonists in therapy, as well as nucleic acids encoding the interferon receptor agonists, recombinant cells that express the interferon receptor agonists and methods of producing the interferon receptor agonists.

公开(公告)号：US11820815B2

公开(公告)日：2023-11-21

申请号：US16892336

申请日：2020-06-04

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Nicholas J. Papadopoulos ,  Joel H. Martin ,  Eric Smith ,  Irene Noguera-Troise ,  Gavin Thurston

IPC分类号： C07K16/22 ,  C07K16/18 ,  A61K39/00

CPC分类号： C07K16/22 ,  C07K16/18 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

摘要： The present invention provides methods of treating, ameliorating, or inhibiting tumor growth, cancer, or pathological angiogenesis by administering to a subject in need thereof a human antibody or fragment thereof that specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The anti-hDll4 antibody or fragment thereof of the present invention have a high affinity with the KD of 500 pM or less, as measured by surface plasmon resonance.

公开(公告)号：US20230357446A1

公开(公告)日：2023-11-09

申请号：US18133288

申请日：2023-04-11

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Eric Smith ,  Dimitris Skokos ,  Kara Olson ,  Lauric Haber ,  Joyce Wei ,  Chia-yang Lin

IPC分类号： C07K16/46 ,  A61P35/00

CPC分类号： C07K16/468 ,  A61P35/00 ,  C07K2317/31

摘要： Provided herein are methods of mediating killing of a tumor cell by administering to the subject a multispecific antigen binding molecule with a first antigen binding region specific for first target antigen and a second antigen binding region specific for a CD28 protein. In some embodiments, the tumor cell does not express the target antigen. In some embodiments, the tumor cell is not predicted to express the target antigen.

公开(公告)号：US20230272111A1

公开(公告)日：2023-08-31

申请号：US17953114

申请日：2022-09-26

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Lauric Haber ,  Eric Smith ,  Marcus Kelly ,  Jessica R. Kirshner ,  Sandra Coetzee ,  Alison Crawford ,  Thomas Nittoli ,  Yashu Liu

IPC分类号： C07K16/30 ,  C07K16/46 ,  A61K39/395 ,  C07K16/28 ,  C07K16/44 ,  A61K47/68 ,  G01N33/574

CPC分类号： C07K16/3092 ,  C07K16/468 ,  A61K39/39558 ,  A61K39/395 ,  C07K16/2863 ,  C07K16/3069 ,  C07K16/44 ,  C07K16/2809 ,  A61K47/6851 ,  A61K47/6869 ,  A61K47/6849 ,  G01N33/57492 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/92 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/73 ,  C07K2317/94 ,  A61K2039/505

摘要： Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

公开(公告)号：US11708407B2

公开(公告)日：2023-07-25

申请号：US17666116

申请日：2022-02-07

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Tong Zhang ,  Erica Pyles ,  Michael Rosconi ,  Nina Liu ,  Supriya Patel ,  Eric Smith ,  Andrew Murphy ,  Chia-Yang Lin ,  Samuel Davis

IPC分类号： C07K16/24 ,  C07K16/28 ,  C07K16/30 ,  A61K47/68 ,  A61K39/395

CPC分类号： C07K16/244 ,  A61K39/395 ,  A61K47/6845 ,  C07K16/2809 ,  C07K16/30 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/52 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

摘要： Antigen binding molecules (ABMs) comprising Fab domains in non-native configurations, ABM conjugates comprising the ABMs and cytotoxic or cytostatic agents, pharmaceutical compositions containing the ABMs and ABM conjugates, methods of using the ABMs, ABM conjugates and pharmaceutical compositions for treating cancer, nucleic acids encoding the ABMs, cells engineered to express the ABMs, and methods of producing ABMs.

公开(公告)号：US20220402989A1

公开(公告)日：2022-12-22

申请号：US17806566

申请日：2022-06-13

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Jiaxi Wu ,  Nicolin Bloch ,  Tong Zhang ,  Chia-Yang Lin ,  Samuel Davis ,  Eric Smith ,  Erica Ullman

IPC分类号： C07K14/55 ,  C07K16/28 ,  C07K14/715 ,  A61P35/00

摘要： The present disclosure relates to a fusion protein comprising an antigen-binding moiety that binds specifically to human PD-1 and an IL2 moiety, and methods of use thereof.

公开(公告)号：US20220233690A1

公开(公告)日：2022-07-28

申请号：US17587501

申请日：2022-01-28

申请人： Regeneron Pharmaceuticals, Inc.

发明人： Kara OLSON ,  Olga Sineshchekova ,  Eric Smith ,  Chiayang Lin

IPC分类号： A61K39/395 ,  A61K38/17 ,  A61K35/17 ,  A61P35/00 ,  A61P37/06

摘要： The present invention provides compositions and methods for treating cancer and inhibiting cytokine release syndrome (CRS). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a CD40 antagonist or a CAR-T cell expressing a CD40 antagonist in combination with a therapeutically effective amount of a CD3 multispecific antigen binding molecule.

公开(公告)号：US11370843B2

公开(公告)日：2022-06-28

申请号：US16774945

申请日：2020-01-28

申请人： REGENERON PHARMACEUTICALS, INC.

发明人： Sean Stevens ,  Tammy T. Huang ,  Joel H. Martin ,  Jeanette L. Fairhurst ,  Ashique Rafique ,  Eric Smith ,  Kevin J. Pobursky ,  Nicholas J. Papadopoulos ,  James P. Fandl ,  Gang Chen ,  Margaret Karow

IPC分类号： C07K16/28 ,  C12N15/12 ,  A61K39/00

摘要： A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a KD of about 500 pM or less and blocks IL-6 activity with an IC50 of 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.